
PROGESTIN-ONLY HORMONAL CONTRACEPTIVES (POHCs)

This decision support tool (DST) provides clinical guidance for the provision of progestin-only hormonal contraception. It is meant to be used in concert with the [Contraceptive Management: Assessment DST](#)

DEFINITION

Progestin-only hormonal contraception is a hormonal contraceptive method that contains only progestin. Three types of POHCs are available in Canada: progestin-only oral contraceptive pills, progestin-only injectable (Depo-Medroxyprogesterone Acetate (DMPA)) and levonorgestrel-releasing intrauterine system. For the purposes of this decision support tool, RN(C)s only autonomously dispense the first 2 methods and therefore POHCs refer only to the first two progestin-only methods of contraception (oral and injectable).

INDICATIONS

For the purpose of contraceptive management certified practice, POHCs are indicated for any client seeking a reliable, reversible, coitally-independent method of contraception. POHCs are a reliable and effective contraceptive option for clients unable to use estrogen-containing contraception. POHCs are further indicated for a number of menstrual-related problems and the non-contraceptive benefits that they might confer. Clients seeking or using POHCs for a sole purpose other than contraception must be referred to a physician or nurse practitioner (NP), for a client specific order or transfer of care.

ACTION

The primary method of action of POHCs is by inhibiting the secretion of pituitary gonadotropins, which then suppresses ovulation. POHCs also make cervical mucus more viscous, which impedes sperm transport. POHCs also induce endometrial atrophy, making the endometrium unreceptive to implantation.

PHARMACOKINETICS

Oral Dose: POHC oral pills are supplied in packages of 28 tablets, each containing 35mcg of norethindron

Injectable DMPA :DMPA is supplied in vials of 150mg to be injected intramuscularly every 12 – 13 weeks (with a range of 10 to less than 15 weeks being acceptable).

Onset

Contraceptive benefits are realized within seven days of consistent and correct POHC use.

BCCNP monitors and revises the BCCNP certified practice decision support tools (DSTs) every two years and as necessary based on best practices. The information provided in the DSTs is considered current as of the date of publication. BCCNP-certified nurses (RN(C)s) are responsible for ensuring they refer to the most current DSTs.

The DSTs are not intended to replace the RN(C)'s professional responsibility to exercise independent clinical judgment and use evidence to support competent, ethical care. The RN(C) must consult with or refer to a physician or nurse practitioner as appropriate, or whenever a course of action deviates from the DST.

CONSULT OR REFER

RN(C)s* are restricted to dispensing or administering POHCs to clients who classify as category 1 or 2 as defined by the *U.S. Medical Eligibility Criteria for Contraceptive Use*. RN(C)s cannot independently dispense or administer POHCs without an order to clients who classify as a category 3 or 4 as defined by the *U.S. Medical Eligibility Criteria for Contraceptive Use*.

Relative Contraindications

As per *U.S. Medical Eligibility Criteria for Contraceptive Use*, Category 3

Absolute Contraindications

As per *U.S. Medical Eligibility Criteria for Contraceptive Use*, Category 4

RN(C)s must refer or consult with a physician or nurse practitioner for the following clients:

- Clients wanting to use a POHC in the presence of relative or absolute contraindications (*U.S. Medical Eligibility Criteria for Contraceptive Use*, categories 3 and 4).
- Clients whose medical condition has changed so that they might be using a POHC in the presence of relative or absolute contraindications (*U.S. Medical Eligibility Criteria for Contraceptive Use*, categories 3 and 4).
- Clients who are currently taking POHCs and demonstrate any of the following symptoms: ACHES (abdominal pain, chest pain, headache, eye problems and severe leg pain); jaundice; syncope; severe depression; unexplained vaginal bleeding; severe or worsening migraine headaches (with or without aura) or severe allergic reaction.
- Clients taking medications that might be affected by hormonal contraception

Drug Interactions

The following drugs and drug classes are considered a category 3 or 4 and could have some effect on POHC absorption and metabolism. Clinicians should always refer to the most current MEC for up to date drug interactions. RN(C)s must refer or consult with a physician or nurse practitioner for clients taking any of the following medications:

* Note: RN(C) is an [authorized title](#) recommended by BCCNP that refers to BCCNP-certified RNs, and is used throughout this Decision Support Tool (DST).

Oral

- Certain anticonvulsants: phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine
- Certain antimicrobial: Rifampicin or Rifabutin therapy (**Note:** Except for Rifampicin or Rifabutin therapy, antibiotic use does not affect POHC efficacy.)

DMPA

- Aminoglutethimide (used to treat Cushing disease) (Not in US MEC but may decrease effectiveness of DMPA)

PREGNANCY AND BREAST/CHEST FEEDING

Pregnancy

There is no known harm to the person, the course of the pregnancy or the fetus if POHCs are inadvertently used during pregnancy. The relation between DMPA use during pregnancy and its effects on the fetus remain unclear. If a POHC is inadvertently initiated with a pregnant client or the client becomes pregnant during POHC use, the POHC should be discontinued immediately.

Postpartum

Initiation of POHCs can occur directly post-partum regardless of breast feeding status.

Breast/Chest feeding

Progestin is excreted in breastmilk in small quantities, but is unlikely to have an effect on the baby. Breastfeeding is not a contraindication for POHC use.

PRECAUTIONS AND CONSIDERATIONS

- Precautions specific to Progestin-Only Oral Contraceptives: patients who have undergone malabsorptive procedures (such as gastric bypass or biliopancreatic diversion) are MEC 3
- Malabsorption related to chronic gastrointestinal inflammation and active diarrhea might cause ineffectiveness of any oral contraception.
- Repeated vomiting (e.g., bulimia) and or severe, persistent diarrhea can decrease the absorption of the pill and might decrease its effectiveness. Vomiting within two hours of pill ingestion might require repeated doses.

Precautions Specific to DMPA

- DMPA is associated with decreased bone mineral density that is generally temporary and reversible. The advantages of DMPA use generally outweigh theoretical concerns regarding fracture risk. The available evidence does not justify limiting duration of DMPA use due to bone

density concerns. Use of DMPA in the absence of symptoms or other risk factors (i.e. strong family history of osteoporosis) is not an indication for bone mineral density testing.

- Clients should be informed about the potential effects of DMPA on bone mineral density and counselled about bone health, including calcium and vitamin D supplements, smoking cessation, weight-bearing exercise, and decreased alcohol and caffeine consumption.
- To rule out a rare but possible severe allergic reaction to DMPA, clinicians should recommend that clients wait 15-20 minutes following injection.
- DMPA might have a slower return to fertility than other hormonal contraceptives. The average return to fertility is 10 months from the last DMPA injection.

ADVERSE EFFECTS

Side effects from POHCs are often mild and transient and respond to a change in formulation.

Acknowledgment and management of side effects are crucial to successful continuation of POHCs.

Common Possible Side Effects

Common side effects of POHCs include, but are not limited to:

- Appetite changes (can result in weight gain)
- Breast tenderness
- Menstrual cycle disturbance: breakthrough bleeding, irregular bleeding, amenorrhea
- Headaches (mild, without aura)
- Decreased libido
- Mood changes
- Delayed return to fertility (for DMPA only)
- Weight Gain (for DMPA only)

Warnings and Precautions

Serious complications from POHCs are rare. The following symptoms should be investigated immediately, referred to a physician or nurse practitioner and might warrant discontinuation of POHCs:

- ACHES (abdominal pain, chest pain, headache, eye problems and severe leg pain)
- Moderate to severe depression
- Blood pressure >160/100 (DMPA is MEC category 3 ; POPs RN (c) may dispense but should consider referral for hypertension assessment).
- Jaundice
- Syncope
- Severe or worsening migraine headaches with or without aura
- Severe allergic reaction

- Unexplained vaginal bleeding

CLIENT EDUCATION SPECIFIC TO POHC USE

- A missed oral POHC pill by more than three hours from the regular time requires use of back up contraception (e.g., condom) for 48 hours. Clients can consider use of emergency contraception if unprotected intercourse occurred within the past 5-7 days.
 - If available, advise the client to follow the product monograph, or advise the client to contact a health care provider or clinic. Some clinics choose to develop client hand-outs or resources specific to missed or late POHC doses. The Society of Obstetricians and Gynecologists of Canada (SOGC) or the US MEC Selected Practice Recommendations for Hormonal Contraceptive Use (2016) have guidelines for missed hormonal contraceptives that can be used as a resource for health care providers.
- Irregular menses is common within the first several months of POHC use. After 6-12 months, amenorrhea is more likely.
- Weight gain is possible with DMPA use and can be used as a teachable moment.
- Clients using DMPA should be counselled regarding calcium intake and or supplementation and encouraged to quit smoking and perform weight-bearing exercises at least three times a week.
- If it has been 14 weeks or more since the last DMPA injection, a urine pregnancy test should be performed. Use of emergency contraception can be considered if intercourse has occurred within the last 5-7 days. A back up method (e.g., condoms) should be recommended for the next seven days. Depending on the client's risk of pregnancy, a repeat urine pregnancy test may be indicated at two weeks or prior to the next injection.

DISPENSING AND ADMINISTERING

For dispensing POHCs, refer to the *Contraceptive Management: Assessment DST*

Administering DMPA

Mix the suspension well by shaking the vial before drawing up the medication. Using a 21-23 gauge needle appropriate for muscle mass, administer 1cc of 150mg/mL DMPA via intramuscular injection into the deltoid or ventrogluteal muscle depending on the client's preference. The ventrogluteal muscle might be less painful for the client. Do not massage the injection site.

MANAGEMENT AND FOLLOW UP

For the purpose of this DST, initiation of hormonal contraception is when no hormonal contraception has been used within the last three months or the client is switching from a CHC to a POHC or from a POHC to a CHC.

Advise a client to return at any time to discuss side effects or other problems or if she wants to change the method being used. No routine follow-up visit is required.

Specific populations that might benefit from more frequent follow-up visits include adolescents, those with certain medical conditions or characteristics, and those with multiple medical conditions.

At other routine visits, when seeing combined hormonal contraceptive users RN (C)s should do the following:

- Assess the client's satisfaction with their contraceptive method and whether they have any concerns about method use.
- Assess any changes in health status, including medications, that would change the appropriateness of combined hormonal contraceptives for safe and effective continued use based on U.S. MEC (e.g., category 3 and 4 conditions)
- Assess blood pressure (at least annually).
- Consider assessing weight changes and counseling women who are concerned about weight changes perceived to be associated with their contraceptive method

DOCUMENTATION

- Refer to the [*Contraceptive Management: Assessment DST*](#).


Appendix 1: POHC Screening Tool

This does not replace the most current practice recommendations, RN (C)s should always check medical eligibility against the most current US MEC.

Are there any relative or absolute contraindications for Progestin-Only Hormonal Contraceptive Use?		
Questions to assist in determining Medical Eligibility for POHC use:		
Have you ever been told you have breast cancer?	NO	YES
Have you ever had a stroke or problems with your heart?	NO	YES
Have you ever been told you have liver disease or jaundice?	NO	YES
Have you ever been told you have diabetes?	NO	YES
Have you ever been told you have lupus or rheumatoid arthritis?	NO	YES
Have you ever been told you have high blood pressure?	NO	YES
Do you have problems with severe diarrhea, poor absorption or other bowel disorders?	NO	YES
Do you get migraine headaches?	NO	YES
Do you have any unexplained vaginal bleeding?	NO	YES
Do you take any medications including natural remedies?	NO	YES
Do you take anti-retroviral medications?	NO	YES
Do you take medications for seizures?	NO	YES
Do you take medications for Cushing disease?	NO	YES
Do you take medications for tuberculosis?	NO	YES

IF YES to any:
STOP – EXPLORE OR REFER
 Client may not be a good candidate for POHC. Counsel about other contraceptive methods or consult/refer to Dr/NP if client is a MEC category 3 or 4.

IF YES to any:
STOP – EXPLORE OR REFER
 Client may not be a good candidate for POHC. Counsel about other contraceptive methods or consult/refer to Dr/NP if client is a MEC category 3 or 4.



REFERENCES

More recent editions of any of the items in the Reference List may have been published since this DST was published. If you have a newer version, please use it.

Anderson, K.C., Schwartz, M.D. and Lieu, S.O. (2013). Antibiotics and OC effectiveness. *Journal of the American Academy of Physician Assistants*, 26(1)11.

Centers for Disease Control and Prevention. (2017). *Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised recommendations for the use of hormonal contraception among women at high risk for HIV infection. Morbidity and Mortality Weekly Report (MMWR)*, 66(37), 990-994. Retrieved from <https://www.cdc.gov/mmwr/volumes/66/wr/mm6637a6.htm>

Centers for Disease Control and Prevention. (2016). *U.S. medical eligibility criteria for contraceptive use, 2016. Morbidity and Mortality Weekly Report*, 65(3), 1-106. Retrieved from <https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6503.pdf>

Dickey, R. P. (2014). *Managing contraceptive pill patients* (15th ed.). Fort Collins, CO: E. M. I. S. Medical Publishing.

Freeman, S., & Shulman, L. P. (2010). Considerations for the use of progestin-only contraceptives. *Journal of the American Academy of Nurse Practitioners*, 22, 81–91.

Grossman Barr, N. (2010). Managing Adverse Effects of Hormonal Contraceptives. *American Family Physician*, 82(12), 1499–1506.

1.

Hatcher, R.A., Nelson, A.L., Trussell, J., Cwiak, C., Cason, P., Policar, M.S., Aiken, A.R.A., Marrasso, J. & Kowal, D. (2019). *Contraceptive technology* (21st. ED.). Atlanta: Managing Contraception, LLC.:GA

Mishra NK, Chowdary KA, Mishra G. Medroxyprogesterone Acetate - A Hormonal Contraceptive. *International Journal of Pharmacology and Therapeutics*. 2016;6(3):10.

Pfizer Canada. (2011). Depo-Provera Product Monograph. (L3) 26 October 2015. https://www.pfizer.ca/sites/g/files/g10028126/f/201512/DEPPROVERA_PM_E.pdf

Society of Obstetricians and Gynaecologists of Canada. (2015). *SOGC Clinical practice guidelines: Canadian contraception consensus (Part 1 to 4)*. Retrieved from <http://sogc.org/wp-content/uploads/2015/11/gui329Pt1CPG1510E.pdf>

World Health Organization. (2015). *Medical eligibility criteria for contraceptive use, 5th Edition*. Retrieved from http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/WHO.

Zieman, M., Hatcher, R. A., Allen, A. Z., Lathrop, E. & Haddad, L. (2017-2018). *Managing contraception on the go* (14th ed). Atlanta, GA: Bridging the Gap Communications